Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans

Parkinson ’s disease is a disabling neurodegenerative movement disorder characterized by dopaminergic neuron loss induced by α-synuclein oligomers. There is an urgent need for disease-modifying therapies for Pa...

Source: Molecular Neurodegeneration - November 12, 2021 Category: Neurology Authors: Kevin S. Chen, Krystal Menezes, Jarlath B. Rodgers, Darren M. O ’Hara, Nhat Tran, Kazuko Fujisawa, Seiya Ishikura, Shahin Khodaei, Hien Chau, Anna Cranston, Minesh Kapadia, Grishma Pawar, Susan Ping, Aldis Krizus, Alix Lacoste, Scott Spangler & hellip; Tags: Research article Source Type: research